Forte Biosciences (NASDAQ: FBRX) nears deal after U.S. antitrust wait expires
Rhea-AI Filing Summary
Forte Biosciences, Inc. (FBRX) reports an update on the pending cash tender offer by Avena Merger Sub Inc., a wholly owned subsidiary of argenx BV, to purchase all outstanding Forte common shares at $77.00 per Share.
The amendment discloses that Forte and argenx filed Premerger Notification and Report Forms under the HSR Act on August 3, 2026, and that the required waiting period expired at 11:59 p.m. Eastern Time on August 18, 2026. The antitrust-related closing condition in the merger agreement tied to HSR waiting-period expiration has therefore been satisfied.
Positive
- None.
Negative
- None.
Key Figures
Tender offer price: $77.00 per Share
Par value per share: $0.001 per share
HSR filing date: August 3, 2026
+2 more
5 metrics
Tender offer price
$77.00 per Share
Cash consideration for each outstanding Forte Biosciences common share in the offer
Par value per share
$0.001 per share
Par value of Forte Biosciences common stock
HSR filing date
August 3, 2026
Date Parent and Forte filed Premerger Notification and Report Forms
HSR waiting period expiration
11:59 p.m. Eastern Time on August 18, 2026
Expiration time and date of the required HSR Act waiting period for the offer
Filing date of amendment
August 19, 2026
Date the Schedule 14D-9 Amendment No. 1 was signed by the CEO
Key Terms
Schedule 14D-9, Offer to Purchase, Premerger Notification and Report Form, HSR Act, +1 more
5 terms
Schedule 14D-9 regulatory
"This Amendment No. 1 to Schedule 14D-9 amends and supplements"
Schedule 14D-9 is a filing with the U.S. Securities and Exchange Commission in which a company publicly states its response and recommendation to an outside bid to buy its shares (a tender offer). Think of it as the company’s advisory note to shareholders explaining whether to sell, keep, or seek alternatives, and why, with facts and reasoning. Investors rely on it to gauge management’s view of the offer’s fairness and the likely impact on value and strategy.
Offer to Purchase financial
"upon the terms and subject to the conditions described in the Offer to Purchase"
An offer to purchase is a formal proposal from one party to buy a specific amount of shares or assets from another party at a set price. It matters to investors because it signals interest in acquiring ownership and can influence the value or control of a company. Think of it as someone putting forward a clear, serious offer to buy something they find valuable.
Premerger Notification and Report Form regulatory
"each of Parent and the Company filed a Premerger Notification and Report Form"
HSR Act regulatory
"The required waiting period under the HSR Act with respect to the Offer"
The HSR Act (Hart‑Scott‑Rodino Antitrust Improvements Act) requires companies in the United States to notify federal regulators and observe a waiting period before completing certain large mergers or acquisitions so authorities can check for anti-competitive effects. For investors it matters because the review can delay or block deals, force changes such as selling assets, and alter the expected value or timing of a transaction—like needing a permit before finalizing a major home renovation.
waiting period regulatory
"the required waiting period under the HSR Act with respect to the Offer expired"
A waiting period is a legally required pause before a corporate action — such as a securities offering, merger, or regulatory approval — can take effect, giving regulators time to review documents and the public time to respond. It matters to investors because it sets when money can change hands and when shares can be traded, creating a window of uncertainty and opportunity much like a cooling-off period before a big purchase.
FAQ
What transaction involving Forte Biosciences (FBRX) is described in this amendment?
Forte Biosciences is the target of a cash tender offer for all outstanding shares at $77.00 per Share by Avena Merger Sub Inc., a wholly owned subsidiary of argenx BV. This amendment provides an update on required U.S. antitrust clearance under the HSR Act.
What HSR Act milestone did Forte Biosciences (FBRX) and argenx achieve?
Forte Biosciences and argenx obtained expiration of the required HSR Act waiting period for the tender offer. The waiting period expired at 11:59 p.m. Eastern Time on August 18, 2026, satisfying the merger agreement condition related to U.S. antitrust clearance for the offer.
When were HSR premerger filings made for the Forte Biosciences (FBRX) tender offer?
On August 3, 2026, both argenx (Parent) and Forte Biosciences filed Premerger Notification and Report Forms with the FTC and the DOJ Antitrust Division. These filings commenced the HSR Act review process required for completing the tender offer transaction.
Who is the acquirer in the Forte Biosciences (FBRX) tender offer structure?
The acquiring structure consists of Avena Merger Sub Inc., a Delaware corporation, as the purchaser, and argenx BV, a Belgian company, as its parent. Avena Merger Sub is a wholly owned subsidiary of argenx and is making the offer to buy all Forte shares.
Does this Forte Biosciences (FBRX) amendment change the tender offer price or terms?
The amendment does not change the previously announced $77.00 per Share offer price or core terms. It specifically updates shareholders that the HSR Act waiting period has expired, thereby satisfying the antitrust-related condition referenced in the merger agreement’s Annex I clause (e)(i).
AI-generated analysis. How Rhea-AI works. Not financial advice.
